CLAIMS

1. Use of a composition comprising: 1) blood plasma orserum; and 2) immunoglobulins directed against a causative agent in the manufacture of a medicament for the prevention of:

an infection and/or transmission with, or

the prevention or treatment of a disease caused by,

said causative agent entering or transmitted through the naso-pharyngeal area in a subject;

wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent, and

wherein said medicament is to be administered intranasally, or in the naso-oropharyngeal area.

2. The use according to claim 1, wherein said causative agent causes a respiratory infectious disease,

wherein said composition comprises: 1) blood plasma or serum and 2) immunoglobulins directed against said causative agent of said respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease; and

wherein said medicament is to be administered intranasally, or in the naso-oropharyngeal area.

3. The use according to claim 1 or 2, wherein the medicament is to be used for preventing or decreasing progression of said infectious disease to the lower respiratory system, into a systemic infection, or to a gastro-enteric infection and/or for preventing transmission of said infectious disease in a population.

4. The use according to any one of claims 1 to 3, wherein the medicament comprises at least 70 % (v/v) of said blood plasma or serum and immunoglobulins directed against said causative agent of said infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said infectious disease.

5. The use according to any one of claims 1 to 4, wherein said blood plasma or serum is not enriched in platelets, preferably wherein said blood plasma is not platelet-rich plasma (PRP).

6. The use according to any one of claims 1 to 4, wherein said composition comprises convalescent blood plasma or serum obtained from a donor subject who has developed a humoral immune response to a causative agent of said infectious disease.

7. The use according to any one of claims 1 to 6, wherein the medicament is to be administered to said subject

- before said subject is being exposed to said causative agent of said infectious disease;

- before said subject is infected by said causative agent of said infectious disease;

- after said subject has been exposed to said causative agent of said infectious disease; or

- after said subject has been infected by said causative agent of said infectious disease.

8. The use according to any one of claims 1 to 7, wherein said causative agent of said infectious disease is a virus, a bacterium, a bacterial spore, or a fungus, preferably a virus.

9. The use according to any one of claims 1 to 8, wherein the respiratory infectious disease is a respiratory infectious disease.

10. The use according to claim 9, wherein said respiratory infectious disease is a viral respiratory infectious disease.

11. The use according to claim 10 wherein said causative agent of said viral respiratory infectious disease is selected from the group consisting of a respiratory syncytial virus (RSV), an influenza virus, and a Coronaviridae virus.12. The use according to claim 11, wherein said Coronaviridae virus is a Severe Acute Respiratory Syndrome-related Coronavirus, most preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; causing COVID-19).

13. The use according to any one of claims 1 to 12, wherein the medicament is a pulmonary aerosolized formulation, a nasal drop, an oro-nasal drop, a nasal spray, an oro-nasal spray, or a naso-oropharyngeal spray.

14. The use according to any one of claims 1 to 13, wherein said medicament is to be used in support of a conventional infectious disease treatment, prophylaxis, or vaccination method, or wherein said medicament is to be used in absence of a conventional infectious disease treatment, prophylaxis, or vaccination method.

15. The use according to any one of claims 1 to 13, wherein said medicament is to be used in absence of a conventional infectious disease treatment, prophylaxis, or vaccination method.

16. A nasal, naso-oropharyngeal, or oro-nasal spray comprising a composition comprising: 1) blood plasma or serum; and 2) immunoglobulins directed against a causative agent of a respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease as defined in any one of claims 1 to 15.

17. A nasal, naso-oropharyngeal, or oro-nasal spray device comprising a composition comprising: 1) blood plasma or serum; and 2) immunoglobulins directed against a causative agent of a respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease as defined in any one of claims 1 to 15.

18. The use according to any one of claims 1 to 15, wherein said medicament is capable of inducing a humoral immune response against said causative agent in a subject..

19. Use of a composition comprising: 1) blood plasma or serum; and 2) immunoglobulins directed against a disease-causing agent, in the manufacture of a medicament for inducing a humoral immune response against said disease-causing agent entering or transmitted through the naso-pharyngeal area in a subject, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said disease-causing agent; and wherein said composition is to be administered intranasally, or in the naso-oropharyngeal area.

20. A method for producing a vaccine, comprising combining a composition comprising: 1) blood plasma or serum; and 2) immunoglobulins directed against a disease-causing agent entering or transmitted through the naso-pharyngeal area, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said disease-causing agent, with one or more pharmaceutically acceptable excipients.